# HERIZON-GEA-01 (NCT05152147)

> A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05152147
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Jazz Pharmaceuticals
- Conditions: Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma
- Interventions: Zanidatamab; Tislelizumab; Trastuzumab; Capecitabine; Oxaliplatin; Cisplatin; 5-Fluorouracil
- Enrollment: 920
- Primary outcome: Progression-free survival (PFS) by BICR
- Primary outcome: Overall survival

## Commentary we found

- X threads: 65
- YouTube: 36
- Podcasts: 23
- X videos: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=herizon-gea-01-nct05152147

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05152147", "email": "<work email>"}; the inbox owner confirms by the emailed link.